17-Allylamino-17-demethoxygeldanamycin (17-AAG) is a new anticancer agent currently in clinical trials. The ability of 17-AAG to abrogate the function of heat-shock protein Hsp90 and modulate cellular sensitivity to anticancer agents has prompted recent research to use this compound in drug combination therapy. Here we report that 17-AAG has striking opposite effects on the activity of arsenic trioxide (ATO) and ara-C. Combination of 17-AAG with ATO exhibited a synergistic effect in leukemia cells, whereas coincubation of 17-AAG and ara-C showed antagonistic activity. Mechanistic studies revealed that ATO exerted cytotoxic action by reactive oxygen species generation, and activated Akt survival pathway. 17-AAG abrogated Akt activation and enhanced the activity of ATO. In contrast, treatment of leukemia cells with 17-AAG caused a G1 arrest, a decrease in DNA synthesis and reduced ara-C incorporation into DNA, leading to antagonism. The ability of 17-AAG to enhance the antileukemia activity of ATO was further demonstrated in primary leukemia cells isolated from patients with acute myeloid leukemia and chronic lymphocytic leukemia, including cells from refractory patients. Our data suggest that combination of 17-AAG and ATO may be an effective therapeutic regimen. Caution should be exercised in using 17-AAG together with ara-C, as their combination effects are schedule dependent.
Introduction
Heat-shock proteins serve as chaperones and are involved in regulation of the intracellular disposition of diverse cellular proteins. 1 The heat-shock protein 90 (Hsp90) is an important molecular component of the chaperone complex that is required for structural folding and maintenance of conformational integrity of its client proteins, many of which are important tyrosine and serine kinases such as c-src and Akt involved in regulation of cell proliferation and cell survival. Inhibition of Hsp90 disrupts the folding of these proteins, thereby increasing their susceptibility to ubiquitination and proteasomal degradation.
2,3 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is a derivative of geldanamycin that is currently undergoing clinical development as a novel anticancer agent for the treatment of human cancers. 4 17-AAG seems to display significant hsp90-dependent antitumor activity while possessing a favorable toxicity profile. 5 This compound binds to Hsp90 and promotes the degradation of various Hsp90 client proteins important in the proliferation and survival of malignant cells. 2, 3, [6] [7] [8] [9] Exposure of cells to 17-AAG or geldanamycin has been shown to cause decreased expression of a variety of signal transduction and cell cycle regulatory proteins, including Raf-1, cyclin D, ErbB and Akt, among others. 10 Akt is a serine threonine kinase that lies downstream of phosphatidylinositol 3-kinase (PI3K) and plays critical role in promoting cell survival. This pathway is frequently dysregulated in human cancers. 11, 12 Although the exact mechanisms by which heat-shock protein antagonists such as 17-AAG kill cancer cells remain to be defined and may vary with cell types, recent evidence suggests that abrogation of the Akt survival pathway may play an important role in this process. 13 Certain differences between chaperoning complexes in neoplastic and normal cells make the Hsp90 complex a potentially useful target for cancer chemotherapy. In particular, it is thought that Hsp90 in neoplastic cells exists in multimolecular complexes with high ATPase activity and high affinity for 17-AAG, whereas in normal cells Hsp90 exists in a latent form that has low ATPase activity and a low affinity for 17-AAG. 14 These observations provide an explanation for the enhanced accumulation and selective cytotoxicity of 17-AAG in neoplastic cells. [14] [15] [16] Recently, the geldanamycin family of antibiotics has been found to induce apoptosis in many malignant cells, including adult chronic myeloid leukemia and acute myeloid leukemia (AML). 17, 18 Based on this selective cytotoxicity against cancer cells, 17-AAG has been developed as a new anticancer agent and is currently in phase I and II trials for treatment of patients with solid tumors. 19, 20 This compound also shows promising activity against leukemia cells in experimental systems, especially in leukemia cells that are resistant to other agents. 17, 18, [21] [22] [23] A recent clinical trial of 17-AAG in patients with advanced cancer showed that this drug did not induce a significant tumor response in phase I setting, 20 suggesting that 17-AAG may not be very effective as a single agent. Thus proper combination of 17-AAG with other anticancer agents should be considered in order to fully utilize the therapeutic potential of this compound for cancer treatment. Because abrogation of the Akt survival pathway by administration of Hsp90 antagonists is expected to increase cellular sensitivity to other anticancer agents, there have been significant interests in using 17-AAG in combination with other anticancer drugs to enhance therapeutic activity. In experimental model systems, combination of 17-AAG with various agents including imatinib, histone deacetylase inhibitors or radiation seems to show encouraging results. 17, 18, [23] [24] [25] [26] How ever, as different anticancer agents have different mechanisms of action, their combinations with 17-AAG may not always lead to enhancement of anticancer activity. A detailed understanding of mechanisms of drug action is essential for the logical design of drug combination strategies to produce optimal therapeutic outcomes.
In the current study, we tested the effect of 17-AAG on the antileukemia activity of arsenic trioxide (ATO) and ara-C, two drugs commonly used in the clinical treatment of leukemia with different mechanisms of action. We observed that 17-AAG significantly enhanced the antileukemia activity of ATO but antagonized the action of ara-C when both compounds were used simultaneously. We then further investigated the mechanisms underlying these opposite effects, and demonstrated that activation of the Akt pathway mediated by reactive oxygen species (ROS) is an important survival mechanism utilized by leukemia cells to protect themselves from the cytotoxic action of ATO. Abrogation of this survival pathway by 17-AAG resulted in synergistic effects in Jurkat and HL-60 cells, as evidenced by colony formation and apoptosis assays. Induction of apoptosis by the drug combination was completely abolished upon addition of an antioxidant N-acetylcysteine (NAC). In a sharp contrast, 17-AAG antagonized the cytotoxic activity of ara-C, due in part to induction of G1 arrest, thus preventing ara-C incorporation into cellular DNA. Our study illustrates the importance of logical combinations of 17-AAG with other anticancer agents based on their mechanisms of action to achieve optimal synergistic activity and to avoid antagonistic effect.
Materials and methods

Reagents
The following antibodies were used for immunoblotting analyses using standard Western blotting procedures: phosphoAkt antibody was purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-b-actin was from Sigma-Aldrich Corp. (St Louis, MO, USA). Anti-Akt1/2 antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). NAC, ara-C and ATO were from Sigma-Aldrich Corp. (St Louis, MO, USA 
Cells and cell culture
The human leukemia cells lines (HL-60 and Jurkat) were cultured at 371C in an atmosphere of 5% CO 2 in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 2 mM L-glutamine. Primary leukemia cells were isolated from fresh samples of heparinized peripheral blood obtained from patients with AML with at least 80% blasts or from patients with chronic lymphocytic leukemia (CLL) after proper informed consent. Mononuclear cells were isolated from the samples by Ficoll density-gradient centrifugation. The primary leukemia cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 2 mM L-glutamine and antibiotics. Incubation of primary cells in fresh medium (no drug) for 48 h usually resulted in about 10-30% of the cells being annexin-V positive, indicating various degrees of 'spontaneous' apoptosis. In all experiments, the drug-induced apoptosis was calculated by subtracting 'spontaneous' apoptosis from total apoptosis of the respective samples.
Colony-forming assays
HL-60 cells were seeded in semisolid medium Methocultt H4230 (Stemcell Technologies, Vancouver, BC, Canada) reconstituted with RPMI 1640 medium supplemented with 10% heat-inactivated FBS and 2 mM L-glutamine. The control cells were plated in a six-well plate at a density of 300 cells/ well, and the drug-treated cells (24 h drug incubation) were plated at 600 cells/well to obtain sufficient number of colonies. Colonies were stained and counted after 14 days in culture. Because the control and drug-treated cells were plated at different densities, the survival colonies of the drug-treated samples were first normalized by dividing the colony number by 2 before comparing with the control samples to calculate the percentage of colony formation. Under these experimental conditions, the colony formation efficiency for control HL-60 cells was 85%.
Assessment of drug-induced apoptosis
Several assays including annexin-V/propidium iodide (PI) double staining, caspase-3 cleavage and analysis of cellular DNA fragmentation were used to analyze apoptosis. For flow cytometry analysis of drug-induced apoptosis, cells were stained with annexin-V-FITC and PI, or with a monoclonal FITCconjugated anti-active caspase-3 antibody according to the manufacturer's instructions (BD Biosciences Pharmingen, San Diego, CA, USA). Data acquisition and analysis were performed using a BD Biosciences FACScan flow cytometer with the CellQuest software. Cells that were positively stained by annexin-V-FITC only (early apoptosis) and positive for both annexin-V-FITC and PI (late apoptosis) were quantified, and both subpopulations were considered as the overall apoptotic cells. To analyze cellular DNA contents, cells were collected after drug incubation as indicated in the figure legends, fixed in 70% ice-cold ethanol, and kept at À201C for at least 14 h. The fixed cells were washed twice with phosphate-buffered saline (PBS), stained with PI (50 mg/ml) in PBS containing 0.2% Tween 20 and 2.5 mg/ml RNase at 41C overnight, and analyzed by flow cytometry. The profiles of cellular DNA contents indicate the distribution of the cells in different phases of the cell cycle and any possible DNA loss due to DNA fragmentation during apoptosis. The cells with a DNA content less than that of G 1 cells were classified as sub-G 1 population and considered as apoptotic cells. ]thymidine (0.2 mCi) at 371C. Samples were then collected, rinsed twice with cold PBS and transferred onto a filter via vacuuming. The filter discs were then washed twice with 5 ml of 0.4 N perchloric acid, followed by washing with 70% ethanol. After drying, the filter discs were placed in scintillation vials, 7 ml of scintillation fluid was added and the level of radioactivity was quantified using a liquid scintillation analyzer (Packard Instrument Co., Downers Grove, IL, USA). To determine the effect of 17-AAG on ara-C incorporation into cellular DNA, the control or 17AAG-treated cells were incubated with 0.5 mM [
3 H]ara-C (1 mCi/ml) at 371C for 4 h.
Samples were then collected, rinsed twice with cold PBS and the radioactivity incorporated into DNA in the acid-insoluble precipitate was quantified by liquid scintillation counting.
Statistical analysis
The statistical significance of differences between experimental conditions was determined using the two-tailed Student's t-test.
To characterize synergistic or antagonistic interactions between agents, median dose-effect analysis was used with a commercially available software program (Calcusyn; Biosoft, Ferguson, MO, USA).
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Results
17-AAG exhibits opposite effects on the antileukemia activity of ATO and ara-C
We first used colony formation assay to evaluate the long-term effect of 17-AAG on the cytotoxic activity of ATO and ara-C, two drugs commonly used in clinical treatment of leukemia. HL-60 cells were treated with 0.5 mM 17-AAG, 1 mg/ml ATO, 0.5 mM ara-C, or the combinations of 17-AAG and ATO or 17-AAG and ara-C simultaneously for 24 h. The cells were then seeded in semisolid medium without drugs for colony formation as described in Materials and methods. As illustrated in Figure 1 , 17-AAG at the concentration of 0.5 mM exhibited only moderate cytotoxicity and 71% cells retained their ability to form colonies. Treatment of HL-60 cells with ATO (1 mg/ml) alone resulted in a loss of 67% colonies (33% of control). Combination of 17-AAG and ATO significantly increased the cell killing effect, and caused a 98% loss of colonies. This is substantially more than an additive effect, which was expected to cause a loss of 77% colonies using the fractional product method (1-0.71 Â 0.33 ¼ 0.77). 29 In contrast, we observed that 17-AAG exerted an antagonistic effect on the cytotoxic activity of ara-C. For instance, incubation of HL-60 cells with 0.5 mM ara-C for 24 h caused a loss of 93% colonies. Addition of 0.5 mM 17-AAG increased colony survival from 7 to 23%, suggesting that this compound somehow protected HL-60 cells from the cytotoxic action of ara-C and promoted cell survival in the long-term colony forming assay.
To further evaluate the apparent synergistic effect of 17-AAG and ATO, we performed a series of experiments to formally analyze the combination effect in two leukemia cell lines (HL-60 and Jurkat), using the median-effect analysis program described by Chou and Talalay. 28 This method predicts that an additive effect would produce a combination index of 1. A combination index of less than 1 indicates a synergistic effect, whereas a combination index of more than 1 suggests an antagonistic effect. Cells were treated for 24 h with increasing concentrations of ATO, 17-AAG or a combination of both agents, and flow cytometry analysis of cells double stained with annexin-V/PI was used to assess the fraction of cells affected by the drug treatment. To facilitate subsequent analysis, we used a fixed concentration for 17-AAG (0.5 mM) in combination with various concentrations of ATO. As shown in Figure 1d , 
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H Pelicano et al combination of 17-AAG and ATO resulted in combination index values of substantially less than 1 at all ATO concentrations tested, suggesting a highly synergistic effect between 17-AAG and ATO in both leukemia cell lines.
Role of ROS in mediating ATO/17-AAG-induced cytotoxicity and Akt activation
Our previous studies showed that ATO causes increased generation of ROS by interfering with the mitochondrial respiration chain function. 30 To further evaluate the synergistic effect of ATO and 17-AAG and the possible underlying mechanisms, HL-60 and Jurkat cells were exposed to both compounds, alone and in combination for 24 h, and the druginduced change in cellular ROS and apoptosis was then assessed by flow cytometry analysis. As shown in Figure 2a and b, treatment of HL-60 and Jurkat cells with 1 mg/ml ATO caused a significant increase of ROS in both cell lines, which is associated with induction of apoptosis as evidenced by positive annexin-V reactivity and caspase-3 cleavage (Figure 2c-f) . In HL-60 cells, incubation with 0.5 mM 17-AAG or 1 mg/ml ATO alone for 24 h caused a moderate amount of apoptosis, whereas combination of the two compounds resulted in a substantial increase in the percentage of cell death. This was also consistently detected by both annexin-V/PI staining and caspase-3 cleavage analysis (Figure 2c and d) . We then examined the role of ROS in mediating the synergistic effect of the ATO/17-AAG drug combination by testing the effect of the antioxidant NAC on drug-induced apoptosis. Addition of NAC to cells treated with 17-AAG and ATO effectively suppressed the cytotoxic effect of the drug combination, as indicated by a substantial decrease in the percentage of cells with annexin-V reactivity (Figure 2c ). This protective effect of NAC was further evidenced by inhibition of caspase-3 cleavage (Figure 2d ) and by increase in cell survival in a colony formation assay (data not shown). It is clear that the antioxidant NAC protected the cells from the cytotoxic effect of ATO and 17-AAG, suggesting that ROS is an important mediator of the cytotoxic action under the drug combination conditions. We further extended these experiments to another human leukemia line, Jurkat cells. Similar synergistic effects of ATO and 17-AAG were observed and the ability of NAC to abrogate the cytotoxic activity of the drug combination was confirmed in both annexin-V reactivity and caspase-3 cleavage assays (Figure 2e and f) .
Because ROS are known to cause activation of the Akt pathway, which may serve as a cellular survival mechanism in response to cytotoxic agent, 31, 32 we postulated that the increase in ROS generation in ATO-treated cells might cause Akt activation to protect cells from cytotoxicity, and that 17-AAG enhanced the cytotoxic action of ATO by abrogating the Akt survival pathway. To test this possibility, we first examined if treatment of HL-60 cells with ATO resulted in Akt activation. As shown in Figure 2g , ATO induced a significant increase in Akt phosphorylation at Ser-473 in a time-dependent manner, with the maximum induction of Akt phosphorylation 6 h after exposure to ATO. The total Akt protein levels remained largely unchanged. 
17-AAG abrogates ATO-induced Akt activation
On the basis of recent studies that Akt is a client protein of the chaperone Hsp90 and is subjected to proteasomal degradation in cells exposed to 17-AAG, 33, 34 we hypothesized that 17-AAG might synergize ATO action through abrogation of the Akt survival pathway, which was activated in ATO-treated cells (Figure 2g ). The ability of 17-AAG to reduce Akt phosphorylation and to decrease Akt protein was first tested by Western blot analysis of protein extracts from cells treated with 17-AAG for various times. Figure 3a shows that 17-AAG caused a rapid decrease in Akt phosphorylation at Ser-473 within several hours after HL-60 cells were exposed to the compound. Most of the Ser-473 phosphorylation signal disappeared within 10 h. Interestingly, phosphorylated Akt (e.g., the activated kinase) levels declined much more rapidly than did total Akt protein level in response to 17-AAG treatment, suggesting that inhibition of Hsp90 chaperone by 17-AAG might cause a change of the Akt protein structural conformation in such a way that phosphorylation at Ser-473 was affected more than the total Akt protein degradation. Combination of 17-AAG with ATO abrogated ATOinduced Akt activation, as evidenced by a significant decrease in Ser-473 phosphorylation to the level lower than the control sample (Figure 3b , compare lane 7 to lane 1).
As 17-AAG seemed to prevent Akt activation induced by ATO, we further examined the effect of drug combination sequences on this process. As shown in Figure 3c , simultaneous incubation of 17-AAG and ATO for 6 h only partially suppressed Akt activation (lane 5), whereas pretreatment of cells with 17-AAG for 6 h followed by a 6 h incubation with ATO exhibited much greater suppression of Akt activation (lane 4). This suppression was not simply owing to a longer exposure to 17-AAG, as a simultaneous incubation of 17-AAG and ATO for 12 h did not show the same degree of Akt suppression (lane 9). It is likely that 17-AAG mainly affected the stability of newly synthesized Akt protein during its maturation and phosphorylation. Once Akt had been induced/activated by ATO, the presence of 17-AAG had only a moderate impact on the overall Akt activation status.
Based on the above observations, we then tested the effect of drug combination sequences on the cytotoxicity. HL-60 cells were pretreated with 0.5 mM 17-AAG, 1 mg/ml ATO or their combinations in various sequences. As shown in Figure 4 , under the experimental conditions, 17-AAG and ATO alone caused only a moderate amount of apoptosis at relatively low drug concentrations. Combination of both agents exhibited greater cell killing. Importantly, the sequence of drug combination made a significant difference in cytotoxic effect even when the same drug concentrations were used. The sequence effect is illustrated in Figure 4b . The 17-AAG-ATO incubation was significantly better than 17-AAG þ ATO simultaneously, whereas the reverse drug treatment sequence (ATO-17-AAG) exhibited significantly less cell killing than the simultaneous incubation. These results were consistent with the sequencedependent abrogation of Akt activation shown in Figure 3c .
17-AAG antagonizes the action of ara-C by blocking its incorporation into DNA.
As 17-AAG reduced the overall cytotoxic activity of ara-C (Figure 1 ), we performed further experiments to examine this antagonistic effect and to investigate the possible underlying mechanism in two leukemia cell lines. HL-60 and Jurkat cells were treated with 0.5 mM ara-C, 0.5 mM 17-AAG or their combination for 24 h, and apoptosis was assessed by flow cytometry analysis of annexin-V staining and caspase-3 cleavage. As shown in Figure 5a and b, the presence of 17-AAG significantly decreased the sensitivity of HL-60 and Jurkat cells to apoptosis induction by ara-C. Because the pharmacological action of ara-C is highly cell cycle specific and depends on its incorporation into DNA during the S phase, we investigated the possibility that the antagonism was due to 17-AAG influencing the cell cycle distribution. Figure 5c shows the cell cycle profiles of HL-60 and Jurkat cells treated with 17-AAG for various times. In HL-60 cells, 17-AAG blocked the cell cycle progression at G1 phase and caused a time-dependent decrease of cells in S phase and G 2 /M phase. This was associated with a significant decrease in DNA synthesis activity and reduction of ara-C incorporation into DNA (Figure 5d and e) . Interestingly, treatment with Protein extracts were subjected to immunoblotting using anti-phospho-Akt (Ser-473), anti-Akt protein and anti-b-actin antibodies. Sequence of drug incubation: s, simultaneously; g/a, preincubation with 17-AAG for 6 h followed by ATO for additional 6 h; a/g, pretreatment with ATO for 6 h followed by 17-AAG for additional 6 h; n, not applicable (single drug incubation).
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H Pelicano et al 17-AAG in Jurkat cells resulted in no apparent G1 arrest, possibly owing to a defect in the G1 checkpoint in these cells. 35 Analysis of [ 3 H]thymidine incorporation showed that 17-AAG caused a 30 and 50% decrease of DNA synthesis activity in Jurkat cells at 18 and 24 h, respectively. Although this suppression of DNA synthesis was less severe than that observed in HL-60 cells, these data suggest that 17-AAG was able to cause a reduction of DNA synthesis in Jurkat cells. The ability of 17-AAG to decrease ara-C incorporation into DNA is likely a key biochemical mechanism responsible for its antagonistic effect on ara-C action. The lower level of DNA synthesis inhibition in Jurkat cells seemed to correlate with less antagonistic effect in apoptosis assay (Figure 5b ). This antagonist effect between ara-C and 17-AAG was also observed in primary leukemic blasts isolated from a patient with AML when the cells were incubated in vitro with ara-C, 17-AAG or their combination for 24 h followed by flow cytometric analysis (data not shown).
Cytotoxic effects of ATO and 17-AAG in primary leukemia isolated from patients
Based on the observations that combination of 17-AAG and ATO exhibited synergistic effect in HL-60 and Jurkat cell lines, we further tested this combination in primary leukemia cells isolated from patients with AML or CLL. As shown in Figure 6a and b, AML cells typically showed a 20-30% 'spontaneous' After incubation, cells were washed with cold phosphate-buffered saline, and the radioactivity incorporated in the acid-precipitable DNA was determined by a filter disc assay as described previously. 59 (e) Inhibition of DNA synthesis by 17-AAG in HL-60 cells and Jurkat cells. Cells were first incubated with 0.5 mM 17-AAG for 18 or 24 h, followed by labeling with [ Comparison of drug combination effect using different drug incubation sequences. Note that 17-AAG-ATO was significantly better than 17-AAG þ ATO simultaneously, whereas ATO-17-AAG was significantly less effective than 17-AAG þ ATO simultaneously. 5 mM) or ATO (0.3 mg/ml) induced additional 15-25% apoptosis by each agent, and combination of the two compounds led to a significant increase in cell killing (35-40%), as measured by annexin-V/PI double staining followed by flow cytometry analysis (P ¼ 0.002 compared to ATO alone). Pretreatment of AML cells for 6 h with 17-AAG resulted in a higher percentage of apoptotic cells (45-55%, P ¼ 0.05), although a longer incubation with 17-AAG alone for additional 6 h did not increase apoptosis (Figure 6b ). These results were consistent with the sequence-dependent abrogation of Akt activation shown in Figure 3c . Similarly, when freshly isolated CLL cells were incubated in vitro with 0.3 mg/ml ATO or 0.5 mM 17-AAG for 24 h, approximately 15-25% apoptotic cells were induced (excluding spontaneous apoptosis at the same time point). Combination of ATO and 17-AAG increased the net cell killing to about 40% (P ¼ 0.006 compared to ATO alone; Figure 6c ). Similar to that in AML cells, preincubation of CLL cells with 17-AAG for 6 h exhibited a greater cell killing effect (P ¼ 0.03). We have also analyzed the drug combination effect on primary leukemia cells isolated from 19 previously untreated CLL patients and from 11 patients with prior chemotherapy history who were refractory to fludarabine. The results showed that combination of ATO and 17-AAG was equally effective in CLL cells isolated from both patient groups (P40.7; Figure 6d ), suggesting that both compounds kill CLL cells by a mechanism different from that of fludarabine, and may be useful in treating fludarabinerefractory CLL.
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Discussion
Compelling evidence suggests that the heat-shock protein family members including Hsp90 and Hsp70 play important roles in cellular protein maturation and disposition of various downstream target proteins with diverse function, 1 and thus affect cell proliferation, differentiation and survival. Of particular interest and relevant to the present studies, Hsp90 has been shown to modulate apoptotic processes by affecting the stability of its client proteins such as Akt. 36, 37 Thus, inhibition of Hsp90 function would abrogate the Akt survival pathway and sensitize cancer cells to certain anticancer agents that may otherwise 
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H Pelicano et al activate the Akt protective mechanism. 17-AAG is an inhibitor of Hsp90 currently in clinical trials. It is important to test its ability to modify the activity of other anticancer agents, seek optimal mechanism-based drug combination strategies that produce the best outcomes and avoid potential antagonistic effect. Both ara-C (cytarabine) and ATO (Trisenox) are effective anticancer agents used clinically in the treatment of certain human leukemia. Cytarabine is one of the most active chemotherapeutic agents for the treatment of AML and it remains the backbone of induction and consolidation regimens, whereas Trisenox is a clinically effective agent in the treatment of acute promyelocytic leukemia. 38, 39 Albeit with somewhat lower efficacy, ATO also induces apoptosis in cancer cells lacking PML-RAR and thus opens a possibility for broader clinical applications of this compound. 40, 41 For example, ATO has been recently tested for the treatment of acute T-cell leukemia in combination with interferon. 42 Considering that activation of the PI3K/Akt pathway is an important factor that affects therapeutic outcomes and that activation of the PI3K/Akt pathway contributes to drug resistance in human leukemia cells, [43] [44] [45] [46] we postulate that the abrogation of the PI3K/Akt pathway by 17-AAG would abolish such a survival mechanism and thus enhance the cytotoxicity of ATO.
Indeed, our data suggest that 17-AAG at a moderate toxic concentration significantly increased the apoptotic response of leukemia cells to ATO, as evidenced by a substantial increase in annexin-V reactivity and activation of caspase-3. Importantly, colony formation assay showed that 17-AAG and ATO have a synergistic effect on long-term cell survival. We and others groups have previously demonstrated that generation of ROS is an important event that mediates ATO-induced apoptosis. 30, [47] [48] [49] [50] It is known that increased ROS may lead to activation of the PI3K/Akt survival pathway, which likely reflects a cellular response to ROS stress in the attempt to survive the drug insult. Furthermore, a recent study suggests that the PI3K/Akt signaling pathway may contribute to resistance to ATO-induced apoptosis in human leukemia cell lines. 50 At the molecular level, 17-AAG effectively abrogated ATO-induced Akt activation. Interestingly, 17-AAG caused a rapid loss of Akt phosphorylation well before depletion of protein levels. The levels of phosphorylated Akt (e.g., the activated kinase) declined much more rapidly than did total Akt protein level in response to 17-AAG treatment. This is consistent with previous observations in another experimental system where inhibition of hsp90 by geldanamycin promotes a rapid PP1 phosphatase-dependent inactivation of Akt in breast cancer cells. 51 Furthermore, preincubation of leukemia cells with 17-AAG followed by ATO appears to be more effective than a simultaneous incubation. It is worth noting that when cells were preincubated with ATO, the ability of 17-AAG to suppress Akt activation was substantially reduced (Figure 3c ). It is likely that by inhibiting Hsp90 function, 17-AAG interferes with the normal conformational change and maturation of Akt protein, and thus mainly affects the newly synthesized Akt. As such, if leukemia cells were first treated with ATO followed by 17-AAG, the ATO-induced Akt activation would have occurred before 17-AAG had a chance to suppress the maturation of Akt. Thus, it is important to consider such sequential drug combinations in designing therapeutic protocols to use 17-AAG and ATO for the treatment of leukemia. In CLL cells, the ability of 17-AAG to abrogate Akt activation and enhance cytotoxicity of ATO is consistent with the recent observation that PI3K pathway seems to play a pivotal role in B-CLL cell survival. 52 It is also important to recognize that the mechanism by which 17-AAG potentiates the activity of ATO might be more complex than solely through abrogation of Akt. Molecular approaches such as the siRNA technology may be useful in further defining the role of Akt abrogation in mediating the drug combination effect.
Furthermore, our study demonstrated that 17-AAG antagonizes the cytotoxic action of ara-C when both agents were used simultaneously. The mechanism of action of ara-C is different from that of ATO. It is known that incorporation of ara-C nucleotide into cellular DNA is the critical pharmacological action that causes its cytotoxic effect in leukemia cells. [53] [54] [55] Our study showed that incubation of HL-60 cells with 17-AAG caused an arrest of cell cycle progression at the G1 phase, leading to a decrease of S-phase cells, a blockage of DNA synthesis and a significant reduction of ara-C incorporation into DNA ( Figure 5 ). This is likely the main biochemical mechanism responsible for the observed antagonistic activity when 17-AAG and ara-C were used simultaneously. Interestingly, 17-AAG caused less cell cycle arrest and was less suppressive to DNA synthesis in Jurkat cells ( Figure 5 ). This was correlated with less antagonistic effect with ara-C in these cells. These data further support the conclusion that blockage of ara-C incorporation into cellular DNA is responsible for the antagonistic effect of 17-AAG. However, it is unclear why 17-AAG was less effective in blocking Jurkat cell cycle progression compared to HL-60 cells. Nevertheless, the data shown in Figure 5 suggest that this compound may cause a partial inhibition of DNA synthesis and possibly a moderate cell cycle arrest at the S phase without a significant change in cellular DNA contents.
It should be pointed out that incorporation of nucleotide analogs into DNA is the key event that triggers cytotoxicity, and this seems to be a common characteristic action of anticancer nucleoside analogs including cytarabine, gemcitabine and fludarabine. 56, 57 Thus, caution should be exercised when one considers using nucleoside analogs together with 17-AAG to avoid a potential antagonistic effect. Based on the mechanisms of action of 17-AAG and nucleoside analogs, it is possible to avoid such antagonistic effect by first treating leukemia cells with a nucleoside analog to allow its incorporation into DNA, followed by 17-AAG, whose cell cycle effect would no longer prevent analog incorporation. Indeed, two recent studies showed that such sequential drug combinations were effective in experimental model systems. 17, 58 Thus, the order of drug administration is a critical factor in such drug combination therapy, and may make a significant difference in therapeutic outcomes. Because the combined effects of ara-C and 17-AAG seem to be schedule dependent, synergistic effect can be achieved when ara-C is given before 17-AAG.
